AU2020266566B2 - Solid forms of a GlyT1 inhibitor - Google Patents

Solid forms of a GlyT1 inhibitor

Info

Publication number
AU2020266566B2
AU2020266566B2 AU2020266566A AU2020266566A AU2020266566B2 AU 2020266566 B2 AU2020266566 B2 AU 2020266566B2 AU 2020266566 A AU2020266566 A AU 2020266566A AU 2020266566 A AU2020266566 A AU 2020266566A AU 2020266566 B2 AU2020266566 B2 AU 2020266566B2
Authority
AU
Australia
Prior art keywords
compound
ppm
solid
peaks
magnetic resonance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020266566A
Other languages
English (en)
Other versions
AU2020266566A1 (en
Inventor
Joe Ju Gao
Peter Sieger
Bing-Shiou Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU2020266566A1 publication Critical patent/AU2020266566A1/en
Application granted granted Critical
Publication of AU2020266566B2 publication Critical patent/AU2020266566B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020266566A 2019-05-01 2020-04-30 Solid forms of a GlyT1 inhibitor Active AU2020266566B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962841401P 2019-05-01 2019-05-01
US62/841,401 2019-05-01
PCT/US2020/030580 WO2020223419A1 (en) 2019-05-01 2020-04-30 Solid forms of a glyt1 inhibitor

Publications (2)

Publication Number Publication Date
AU2020266566A1 AU2020266566A1 (en) 2021-11-11
AU2020266566B2 true AU2020266566B2 (en) 2025-11-06

Family

ID=70740812

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020266566A Active AU2020266566B2 (en) 2019-05-01 2020-04-30 Solid forms of a GlyT1 inhibitor

Country Status (25)

Country Link
US (2) US11447474B2 (https=)
EP (1) EP3962911A1 (https=)
JP (2) JP7513349B2 (https=)
KR (1) KR20220004174A (https=)
CN (1) CN113784966B (https=)
AR (1) AR118839A1 (https=)
AU (1) AU2020266566B2 (https=)
BR (1) BR112021020883A2 (https=)
CA (1) CA3138288A1 (https=)
CL (2) CL2021002837A1 (https=)
CO (1) CO2021014260A2 (https=)
CR (1) CR20210545A (https=)
DO (1) DOP2021000224A (https=)
EA (1) EA202192925A1 (https=)
EC (1) ECSP21082195A (https=)
IL (1) IL287630A (https=)
JO (1) JOP20210295A1 (https=)
MA (1) MA55801A (https=)
MX (1) MX2021013341A (https=)
PE (1) PE20212263A1 (https=)
PH (1) PH12021552741A1 (https=)
SG (1) SG11202111972YA (https=)
TW (1) TW202106680A (https=)
UA (1) UA129159C2 (https=)
WO (1) WO2020223419A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7930336B2 (en) 2006-12-05 2011-04-19 Altera Corporation Large multiplier for programmable logic device
EA202192925A1 (ru) * 2019-05-01 2022-03-23 Бёрингер Ингельхайм Интернациональ Гмбх Твердые формы ингибитора glyt1
US11813257B2 (en) 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
MX2023001818A (es) * 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking
WO2025140479A1 (zh) * 2023-12-29 2025-07-03 苏州科睿思制药有限公司 Iclepertin的晶型及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013017657A1 (en) * 2011-08-03 2013-02-07 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
RS20060190A (sr) * 2003-10-14 2008-08-07 Pfizer Products Inc., Biciklični /3.1.0/ derivati kao inhibitori transportera glicina
CA2745690A1 (en) * 2008-12-04 2010-06-10 Evgeny Zlotinikov Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative
EP2381941A4 (en) * 2008-12-29 2012-08-01 Univ Vanderbilt 3.1.0 BICYCLIC GLYTI INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
IL270155B (en) * 2017-04-27 2022-07-01 Takeda Pharmaceuticals Co Heterocyclic compound
EA202192925A1 (ru) * 2019-05-01 2022-03-23 Бёрингер Ингельхайм Интернациональ Гмбх Твердые формы ингибитора glyt1
MX2023001818A (es) * 2020-08-13 2023-03-13 Boehringer Ingelheim Int Compuestos para usarse en tratamiento de deterioro cognitivo asociado con la esquizofrenia.
IL301829A (en) * 2020-10-13 2023-06-01 Boehringer Ingelheim Int Process of reworking

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013017657A1 (en) * 2011-08-03 2013-02-07 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament

Also Published As

Publication number Publication date
CN113784966B (zh) 2024-07-19
JOP20210295A1 (ar) 2023-01-30
JP2024100792A (ja) 2024-07-26
DOP2021000224A (https=) 2021-12-15
TW202106680A (zh) 2021-02-16
NZ781254A (en) 2025-03-28
CR20210545A (es) 2021-12-23
JP7714727B2 (ja) 2025-07-29
JP2022530630A (ja) 2022-06-30
CL2021002837A1 (es) 2022-07-29
PH12021552741A1 (en) 2022-07-11
PE20212263A1 (es) 2021-11-29
CA3138288A1 (en) 2020-11-05
EA202192925A1 (ru) 2022-03-23
EP3962911A1 (en) 2022-03-09
ECSP21082195A (es) 2021-12-30
WO2020223419A1 (en) 2020-11-05
MX2021013341A (es) 2021-11-17
US11447474B2 (en) 2022-09-20
MA55801A (fr) 2022-03-09
US20220332710A1 (en) 2022-10-20
AR118839A1 (es) 2021-11-03
CL2024000829A1 (es) 2024-09-27
KR20220004174A (ko) 2022-01-11
IL287630A (en) 2021-12-01
US20200347041A1 (en) 2020-11-05
SG11202111972YA (en) 2021-11-29
AU2020266566A1 (en) 2021-11-11
JP7513349B2 (ja) 2024-07-09
CO2021014260A2 (es) 2021-10-29
UA129159C2 (uk) 2025-01-29
BR112021020883A2 (pt) 2022-04-19
CN113784966A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
AU2020266566B2 (en) Solid forms of a GlyT1 inhibitor
JP5315244B2 (ja) アザビシクロヘキサン誘導体の使用
EP3703680B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2020503298A (ja) 単環式ｏｇａ阻害剤化合物
JPH10509150A (ja) 酸化窒素シンターゼ阻害剤としてのサイクリックアミジンアナログ
MX2012015170A (es) Derivados de 3-amino-5,6-dihidro-1h-pirazin-2-ona utiles para el tratamiento de la enfermedad de alzheimer y otras formas de demencia.
CA3222197A1 (en) Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
JP2024509875A (ja) アルツハイマー病又は認知症を治療するための医薬組成物
KR20230021075A (ko) 베타 아드레날린성 작용제의 형태 및 조성물
CN111051304A (zh) 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉衍生物
JP2022036285A (ja) ピペリジニルノシセプチン受容体化合物
JP5139306B2 (ja) 電位依存性ナトリウムチャネルの調節因子としての第四級α−アミノカルボキサミド誘導体
US20060030602A1 (en) (S)-amlodipine malate
EA045384B1 (ru) Твердые формы ингибитора glyt1
EP0252643A1 (en) Pyrido[1,2-a]indole derivatives, process for their preparation and pharmaceutical compounds containing them
JP2007502802A (ja) ビフェプルノックスメシラートの安定な多形体
KR102399374B1 (ko) 알츠하이머병의 치료를 위한 ｎ-[2-(6-플루오로-1ｈ-인돌-3-일)에틸]-3-(2,2,3,3-테트라플루오로프로폭시)벤질아민 히드로클로라이드의 신규한 다형체 형태
MX2007006842A (es) Derivados de arilpiperazina y uso de los mismos como ligantes receptores de 5-ht1a.
EP0771798A1 (en) Novel polymorphs of lesopitron dichlorohydrate and its hydrated forms, preparation methods and compositions containing them
EP2315762A2 (en) Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity
HK40028779A (en) Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
JP2013507420A (ja) パルドプルノックスの多形
JPWO2006121104A1 (ja) ピペリジン環を有するインドール誘導体の結晶およびその製法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)